Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Canertinib |
Synonyms | |
Therapy Description |
Canertinib (CI-1033) is a pan-ERBB inhibitor that inhibits EGFR, ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4) signaling, which may result in decreased tumor growth (PMID: 11706399, PMID: 17342332, PMID: 30425998). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Canertinib | CI-1033 | EGFR Inhibitor (Pan) 62 HER inhibitor (Pan) 6 | Canertinib (CI-1033) is a pan-ERBB inhibitor that inhibits EGFR, ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4) signaling, which may result in decreased tumor growth (PMID: 11706399, PMID: 17342332, PMID: 30425998). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|